Project description
A smart way to improve the diagnosis and therapy of colorectal cancer
Artificial intelligence is expected to personalise treatment of colorectal cancer and reduce the incidence and mortality rates. This is the aim of the EU-funded OperA project. Specifically, it will carry out a Europe-wide, population-based, randomised trial to establish the value of AI-assisted colonoscopy in colorectal cancer prevention. Overall, the project's goal is to drastically improve colorectal cancer care. It will also produce a risk-prediction tool for personalised treatment and cost-effective models of AI-assisted colonoscopy in colorectal cancer screening. OperA will also address the ethical and legal barriers to AI development and implementation.
Objective
Integration of artificial intelligence (AI) technologies into clinical medicine has been hampered by challenges related to uncertain long-term clinical benefits, cost-effectiveness, and ethics/legal concerns. Application of AI in colonoscopy, a forefront research topic, has been also bothered by these issues. AI is, however, expected to reduce colorectal cancer incidence and mortality through personalised treatment. Our proposed project would change this discouraging situation and thus drastically improves colorectal cancer care. We achieve the following goals:
1. Establish the value of AI-assisted colonoscopy in colorectal cancer prevention by conducting a pan-European,
population-based, randomised trial with 222,000 participants.
2. Develop a colonoscopy AI risk-prediction tool for personalized treatment of colorectal polyps and cancer.
3. Develop cost-effectiveness models of AI-assisted colonoscopy in colorectal cancer screening.
4. Investigate ethical and legal barriers in AI development and implementation.
5. Generate the first trustworthy and rapidly updating (?living?) clinical guidelines for AI in screening colonoscopy.
6. Develop a patient-oriented AI tool by including end-users in the process of AI development and communication.
Our research consortium maximises the feasibility of the project, with world-class experts in gastroenterology, machine learning, cancer screening, biostatistics, disease modelling, regulatory science, and ethics and law in medicine from nine European countries, the US and Japan. We also partner with a European medium-size AI enterprise for implementing the output of the project. The project has large potential impact on patients, society, and economy in Europe, and the World. Up to 6,000 fewer deaths due to colorectal cancer and saving of 720 million euro can be expected per year once the technology is widely accepted in Europe.
Fields of science
Programme(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
0313 Oslo
Norway
See on map
Participants (12)
0450 Oslo
See on map
0456 Oslo
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
8000 Aarhus C
See on map
17177 Stockholm
See on map
02-781 Warszawa
See on map
08036 Barcelona
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
08036 Barcelona
See on map
20100 Rozzano (Mi)
See on map
20251 Hamburg
See on map
10561 Athina
See on map
02105 Boston Ma
See on map
16802 7000 UNIVERSITY PARK PA
See on map
Partners (5)
SE5 9RS London
See on map
WC1E 6BT London
See on map
EC4A 3TR London
See on map
142-8555 Tokyo
See on map
464 8601 Nagoya
See on map